Friedberg: Retatride triple agonist phase 3 data shows 'wonder drug' potential, FDA 2027
Retatride (triple GLP-1/GIP/glucagon agonist) shows 37lb weight loss vs 6lb placebo, 80% liver fat reduction, 27% non-HDL cholesterol drop, 41% triglyceride drop, A1C 7.9% to 6% i…